Linked Life Data

16455894

Source:http://linkedlifedata.com/resource/pubmed/id/16455894

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16455894rdf:typepubmed:Citationlld:pubmed
pubmed-article:16455894lifeskim:mentionsumls-concept:C0220847lld:lifeskim
pubmed-article:16455894lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:16455894lifeskim:mentionsumls-concept:C0019163lld:lifeskim
pubmed-article:16455894lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16455894lifeskim:mentionsumls-concept:C0035668lld:lifeskim
pubmed-article:16455894lifeskim:mentionsumls-concept:C0021747lld:lifeskim
pubmed-article:16455894lifeskim:mentionsumls-concept:C0035525lld:lifeskim
pubmed-article:16455894lifeskim:mentionsumls-concept:C0444669lld:lifeskim
pubmed-article:16455894lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:16455894lifeskim:mentionsumls-concept:C0430420lld:lifeskim
pubmed-article:16455894lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:16455894pubmed:issue2lld:pubmed
pubmed-article:16455894pubmed:dateCreated2006-2-3lld:pubmed
pubmed-article:16455894pubmed:abstractTextTrak-C (Ortho-Clinical Diagnostics) is an enzyme-linked immunosorbent assay-based method capable of quantifying hepatitis C virus (HCV) core antigen (CA) in serum and could be an alternative to molecular detection and quantification of HCV RNA. We have evaluated the Trak-C assay in comparison with an HCV RNA quantitative assay (Versant HCV v3.0; Bayer Diagnostics) in the follow-up of 348 treated, human immunodeficiency virus (HIV)/HCV-coinfected patients included in the ANRS HC02 RIBAVIC trial. ANRS HC02 RIBAVIC is a therapeutic, multicenter, randomized protocol comparing the efficacy of alpha interferon 2b (IFN-alpha2b) (3 million units three times a week)-ribavirin (800 mg/day) to that of pegylated IFN-alpha2b (1.5 mug/kg of body weight/week)-ribavirin (800 mg/day) during 48 weeks of treatment of HIV/HCV-coinfected patients naïve to HCV treatment. Patients were assessed for virological analysis at day 0 and weeks 4, 12, 24, 48, and 72. Correlation of HCV RNA and HCV CA at the initiation of treatment was excellent (r = 0.92). HCV RNA and CA kinetics were similar during follow-up of HCV treatment from day 0 to week 72 whatever the group of response and genotype. The positive and negative predictive values of response to the treatment at week 4 were 59 and 94%, respectively, for HCV RNA load reduction of >2 log and 54 and 94%, respectively, for HCV CA below the threshold value (4.18 log(10) pg/ml . 10(4)). Trak-C, a new assay able to quantify CA in HIV/HCV-coinfected patients, correlates well with quantitative HCV RNA assays and is cheaper and easier to perform than molecular technology. HCV CA could be a valuable alternative test for therapeutic follow-up of coinfected patients treated with IFN plus ribavirin in developing countries.lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:languageenglld:pubmed
pubmed-article:16455894pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:citationSubsetIMlld:pubmed
pubmed-article:16455894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16455894pubmed:statusMEDLINElld:pubmed
pubmed-article:16455894pubmed:monthFeblld:pubmed
pubmed-article:16455894pubmed:issn0095-1137lld:pubmed
pubmed-article:16455894pubmed:authorpubmed-author:MorandPPlld:pubmed
pubmed-article:16455894pubmed:authorpubmed-author:WuP PPPlld:pubmed
pubmed-article:16455894pubmed:authorpubmed-author:LunelFFlld:pubmed
pubmed-article:16455894pubmed:authorpubmed-author:CacoubPPlld:pubmed
pubmed-article:16455894pubmed:authorpubmed-author:PerronneCClld:pubmed
pubmed-article:16455894pubmed:authorpubmed-author:CarratFFlld:pubmed
pubmed-article:16455894pubmed:authorpubmed-author:PayanCClld:pubmed
pubmed-article:16455894pubmed:authorpubmed-author:PivertAAlld:pubmed
pubmed-article:16455894pubmed:authorpubmed-author:Fafi-KremerSSlld:pubmed
pubmed-article:16455894pubmed:authorpubmed-author:DeshayesJJlld:pubmed
pubmed-article:16455894pubmed:issnTypePrintlld:pubmed
pubmed-article:16455894pubmed:volume44lld:pubmed
pubmed-article:16455894pubmed:ownerNLMlld:pubmed
pubmed-article:16455894pubmed:authorsCompleteYlld:pubmed
pubmed-article:16455894pubmed:pagination417-22lld:pubmed
pubmed-article:16455894pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:meshHeadingpubmed-meshheading:16455894...lld:pubmed
pubmed-article:16455894pubmed:year2006lld:pubmed
pubmed-article:16455894pubmed:articleTitleComparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.lld:pubmed
pubmed-article:16455894pubmed:affiliationLaboratoire de Bactériologie-Virologie-Hygiène Hospitalière, CHU Angers, 4 rue Larrey, 49933 ANGERS Cedex, France.lld:pubmed
pubmed-article:16455894pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16455894pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16455894pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:16455894pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16455894pubmed:publicationTypeMulticenter Studylld:pubmed